Naples, Fla. – April 30, 2026 – The NCH Rooney Heart Institute is among the first in the United States to offer the newly FDA-approved Medtronic Mosaic™ Neo surgical mitral valve, marking a significant advancement in the treatment of patients requiring mitral valve replacement.
The innovative bioprosthetic valve, recently approved by the U.S. Food and Drug Administration (FDA), expands surgical options for patients with mitral valve disease, offering enhanced durability and improved performance.
The Medtronic Mosaic Neo Mitral Valve is designed to provide a durable, tissue-based replacement option for patients requiring mitral valve intervention, particularly those who may not be candidates for long-term anticoagulation therapy. Built on a legacy platform with enhanced design features, the valve aims to optimize hemodynamic performance while supporting ease of implantation for cardiac surgeons. Its development reflects continued advancements in structural heart technology focused on improving patient outcomes, reducing complications, and expanding treatment options for individuals with complex valvular disease.
The first procedures at NCH were performed by leading cardiothoracic surgeons Joseph Lamelas, MD, and Tommy Caranasos, MD, underscoring the Institute’s continued commitment to bringing advanced cardiac care to Southwest Florida.
“This new valve technology represents an important step forward in how we treat complex mitral valve disease,” said Joseph Lamelas, MD, Director, Minimally Invasive Heart Surgery Program at NCH Rooney Heart Institute. “Being among the first to offer Mosaic Neo allows us to provide our patients with the latest surgical innovations while maintaining the highest standards of safety and outcomes.”
“Our goal is always to match the right therapy to the right patient,” said Tommy Caranasos, MD, Vice president, NCH Rooney Heart Institute and the James and Jaimie Yeh Endowed Chair. “The availability of Mosaic Neo enhances our ability to tailor surgical solutions and improve long-term quality of life for those we serve.”
The milestone reflects the NCH Rooney Heart Institute’s ongoing investment in cutting-edge cardiovascular therapies, clinical expertise, and patient-centered care. As one of the region’s leading heart programs, the Institute continues to expand access to advanced procedures typically available only at major academic medical centers.
###